NasdaqGS:ONCBiotechs
BeOne Medicines (ONC): Valuation Insight Following Positive Sonrotoclax Trial Results
BeOne Medicines (NasdaqGS:ONC) delivered an update that is catching investors’ attention, announcing positive topline data from a Phase 1/2 trial for sonrotoclax in relapsed or refractory mantle cell lymphoma. The study met its primary endpoint.
See our latest analysis for BeOne Medicines.
Despite a recent stretch of volatility, with the share price easing 4.7% over the last day but still up an impressive 74% year-to-date, BeOne Medicines has been gaining momentum following encouraging...